MENÚ
Publicaciones
TELÉFONOS HOSPITAL LUCUS AUGUSTI
Información
982 295475
982 295475
Att. Paciente
982 297029
982 297029
Admisión
982 266480
982 266480
Cita Previa
982 296008
982 296008
04 de Septiembre de 2019
Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab.
2019 Sep 4. doi: 10.1111/all.14035.
01 de Septiembre de 2019
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
Pract. 2019 Sep - Oct;7(7):2277-2283.e2. doi: 10.1016/j.jaip.2019.01.017.
01 de Agosto de 2019
Should Lung Function Be Included in the Risk Stratification of Chronic Obstructive Pulmonary Disease Proposed by GesEPOC?
2019 Aug;55(8):436-437. doi: 10.1016/j.arbres.2018.12.007.
01 de Junio de 2019
Comparison of the prognostic capability of two comorbidity indices in patients with chronic obstructive pulmonary disease, in real-life clinical practice.
2019 Jun;13(6):404-407.
01 de Mayo de 2019
Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study.
2019 May;151:49-54. doi: 10.1016/j.rmed.2019.03.006.
01 de Abril de 2019
A Simple Score for Future Risk Prediction in Patients with Controlled Asthma Who Undergo a Guidelines-Based Step-Down Strategy.
Pract. 2019 Apr;7(4):1214-1221.e3. doi: 10.1016/j.jaip.2018.10.017.
